Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 8:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 271 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Respiratory Distress Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Long COVID-19 Intervention Using Digital Health & Technology

NCT05616806
View directory record Official record
Conditions
Long COVID, Distress Tolerance
Interventions
iENDURE
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 10, 2026, 8:10 PM EDT
Terminated Phase 1Phase 2 Interventional

RAPA-501-Allo Therapy of COVID-19-ARDS

NCT04482699
View directory record Official record
Conditions
Severe COVID-19 Disease
Interventions
RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo
Biological · Other
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 10, 2026, 8:10 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 10, 2026, 8:10 PM EDT
Completed No phase listed Observational

IPV and Lung Compliance in Invasively Ventilated Children

NCT06836050
View directory record Official record
Conditions
Pediatric Acute Respiratory Distress Syndrome (PARDS), Pediatric Respiratory Diseases, Lung Compliance
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
0 Days to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 10, 2026, 8:10 PM EDT
Not yet recruiting Not applicable Interventional

Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells - Intensive Care Unit

NCT07811180
View directory record Official record
Conditions
Glucose, Metabolism, Isotope Labeling, Immune System and Related Disorders, Critical Illness, Intensive Care Unit (ICU), Sepsis
Interventions
13C6-Glucose
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 10, 2026, 8:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

NCT04334148
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
1,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
34
States / cities
Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 10, 2026, 8:10 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

NCT04429555
View directory record Official record
Conditions
Pneumonia, Viral
Interventions
Ibudilast, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Denver, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 10, 2026, 8:10 PM EDT
Suspended Phase 2 Interventional

Pediatric Acute Respiratory Distress Syndrome (ARDS) Management Trial

NCT07123961
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), Ventilator Management, Lung-protective Ventilation, Pediatric Acute Respiratory Distress Syndrome (PARDS)
Interventions
High Driving Pressure Mechanical Ventilation, Low Driving Pressure Mechanical Ventilation
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Weeks to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 10, 2026, 8:10 PM EDT
Completed Not applicable Interventional Results available

Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure

NCT01680783
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Shock, Ventilatory Failure, Cardiogenic Pulmonary Edema
Interventions
Non invasive ventilation using a helmet hyperbaric device, Noninvasive ventilation via facemask
Device · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 10, 2026, 8:10 PM EDT
Terminated Phase 2 Interventional

Activated Protein C to Treat Acute Lung Injuries

NCT00112164
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Xigris
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
9
States / cities
Fresno, California • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 10, 2026, 8:10 PM EDT
Recruiting Phase 2 Interventional

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

NCT06701669
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort B: paridiprubart, Cohort B: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 10, 2026, 8:10 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

T-Cell Mitochondrial Respiration Response to Ketone Monoester Supplement in Healthy Volunteers and COVID-19

NCT05798260
View directory record Official record
Conditions
COVID-19 Acute Respiratory Distress Syndrome
Interventions
Agilent Seahorse XF Cell Mito Stress Test
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 10, 2026, 8:10 PM EDT
Completed Phase 4 Interventional

Sleep Intervention During Acute Lung Injury

NCT01050699
View directory record Official record
Conditions
Critical Illness, Sleep, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
Dexmedetomidine, Midazolam and Fentanyl
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 10, 2026, 8:10 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

NCT04466098
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
Interventions
Mesenchymal stromal cells, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 10, 2026, 8:10 PM EDT
Completed Phase 1 Interventional Results available

Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)

NCT04530604
View directory record Official record
Conditions
COVID, Sars-CoV2, COVID-19, Acute Respiratory Distress Syndrome
Interventions
Defibrotide
Drug
Lead sponsor
Gregory Yanik
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 10, 2026, 8:10 PM EDT
Completed No phase listed Observational

Observational Cohort Study of Distribution of Ventilation in Pediatrics Requiring Mechanical Ventilation by Electrical Impedance Tomography

NCT02247700
View directory record Official record
Conditions
Respiratory Failure, Acute Respiratory Distress Syndrome, Acute Lung Injury
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Day to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 10, 2026, 8:10 PM EDT
Terminated Phase 3 Interventional

Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)

NCT00609180
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Minimal (Trophic) Feeding, Full Feeding, Omega-3 Fatty Acids and Antioxidant Supplements, Placebo
Behavioral · Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Sep 10, 2026, 8:10 PM EDT
Not listed No phase listed Observational

Effect of Randomization to Neuromuscular Blockade on Physical Functional Impairment and Recovery in ARDS

NCT03038906
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Neuromyopathies
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 10, 2026, 8:10 PM EDT
Terminated Phase 2 Interventional Results available

Tocilizumab for Patients With Cancer and COVID-19 Disease

NCT04370834
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis, Severe Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Tocilizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Rockville, Maryland • Las Vegas, Nevada • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 10, 2026, 8:10 PM EDT
Completed Not applicable Interventional Results available

A Study Promoting Critical Illness Recovery in the Elderly

NCT02963558
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Critical Illness, Critical Care
Interventions
cycle ergometry
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 10, 2026, 8:10 PM EDT
Completed Phase 2 Interventional Results available

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

NCT04478071
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus Infection
Interventions
vadadustat, placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 10, 2026, 8:10 PM EDT
Terminated Phase 4 Interventional

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

NCT04397510
View directory record Official record
Conditions
Covid-19, ARDS, Human, Acute Lung Injury
Interventions
Heparin, 0.9% Sodium-chloride
Drug
Lead sponsor
Frederick Health
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Sep 10, 2026, 8:10 PM EDT
Completed Phase 2 Interventional Results available

Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome

NCT03818854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Human Mesenchymal Stromal Cells, Cell Reconstitution Media
Biological
Lead sponsor
Michael A. Matthay
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Sacramento, California • San Francisco, California • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 10, 2026, 8:10 PM EDT
Withdrawn Early Phase 1 Interventional

N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome

NCT03346681
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
N-acetyl cysteine
Drug
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 10, 2026, 8:10 PM EDT